Audio Recap: Managing ART Failure
Managing ART Failure: Answering the Questions

Released: August 03, 2023

Daniel R Kuritzkes
Daniel R Kuritzkes, MD
Cristina Mussini
Cristina Mussini, MD

Activity

Progress
1
Course Completed

In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:

  • The definitions of virologic blips, low-level viremia, and virologic failure on ART
  • The infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real world
  • The potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factors
  • The impact of adherence on viral suppression with BIC- and DTG-based ART
  • Drug-drug interactions as a reason for failure of first-line INSTI-based ART
  • What to do if someone is experiencing virologic failure requiring an ART change
  • The use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experience
  • The impact of high HIV-1 RNA on ART effectiveness
  • The impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ART
  • Strategies to encourage and measure patient adherence to ART